Press Release Details

Cerus Corporation Names Bruce Cozadd to Board of Directors

November, 15 2001
Cerus Corporation (Nasdaq: CERS) today announced that Bruce C. Cozadd, former executive vice president and chief operating officer of ALZA Corporation, has joined its board of directors. Mr. Cozadd joins the board with over 15 years of finance and operations experience.

“We are tremendously pleased to have Bruce join our board, particularly as we gear up for commercialization of our INTERCEPT Blood Systems to improve the safety of the global blood supply,” said Stephen T. Isaacs, president and chief executive officer of Cerus. “Bruce is a proven business strategist who we believe will be an effective contributor during our transition to a revenue generating company and beyond.”

Mr. Cozadd, 38, will fill a board position formerly held by Dale A. Smith, who died earlier this year.

Mr. Cozadd was most recently executive vice president and chief operating officer of ALZA Corporation, a leading pharmaceutical company where he served a ten-year tenure. He joined ALZA in 1991 and under his leadership the organization experienced rapid revenue and earnings growth, ultimately achieving $1.1 billion in total revenue prior to the company's acquisition by Johnson & Johnson. Also during his tenure, ALZA completed more than $1 billion in financings and a $580 million acquisition of SEQUUS Pharmaceuticals, Inc., a biotechnology company. Prior to ALZA, Cozadd was a member of the health care investment banking team at Smith Barney, Harris Upham & Co. where he completed numerous transactions for hospital management, health care services, medical products, pharmaceutical and biotechnology companies. Cozadd received a bachelor's of science in Molecular Biophysics & Biochemistry and Economics from Yale University, and his master's of business administration from Stanford's Graduate School of Business. Mr. Cozadd currently serves on the boards of directors of EKOS Corporation, Genencor International and LabVelocity, Inc.


Cerus Corporation is developing medical systems and therapeutics based on its proprietary Helinx™ technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the blood products used for transfusion. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

Helinx is a trademark of Cerus Corporation

INTERCEPT Blood System is a trademark of Baxter International Inc.

Statements in this news release regarding commercialization, regulatory process and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any clinical trials, action by regulatory authorities, the uncertainty of market acceptance of any products or competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1999 Annual Report on Form 10-K and Cerus' Prospectus dated November 1, 2000.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600